Back to Search
Start Over
[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].
- Source :
-
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2007 Jan; Vol. 29 (1), pp. 66-9. - Publication Year :
- 2007
-
Abstract
- Objective: To evaluate the safety and efficacy of gefitinib as second-line or even third-line treatment for previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).<br />Methods: 156 patients with locally advanced NSCLC which were about to undergo progression after previous chemotherapy were eligible for this study. The regimen was oral intake of gefitinib 250 mg once daily in the morning or afternoon until the disease progression or toxicity has become intolerable. The drug was provided by AstroZeneca Company by its Expanded Access Program.<br />Results: 154 such patients were evaluable for response and toxicity assessment. The overall rate of objective response and disease control was 28.6% (44/154) and 89.6% (138/154). The median duration of response was 7. 5 months. The median time to disease progression (TTP) was 5. 1 months and the median overall survival time (OS) 10.0 months. The actuarial 1-year survival was 41. 0%. The response rate in adenocarcinoma was significantly higher than that in squamous carcinoma (P = 0. 026). The risk of disease progression in patients with squamous carcinoma was 1. 7 times as much as that of adenocarcinoma patients ( P = 0. 011) , and the risk of death in male was 2. 0 times as much as that in female ( P = 0. 002). At least one of these adverse events would be observed in 40.9% (63/154) of these patients, which, however was mild and reversible. Conclusion Gefitinib is effective and safe as a second-line or third-line treatment for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
- Subjects :
- Adenocarcinoma drug therapy
Adenocarcinoma pathology
Aged
Antineoplastic Agents adverse effects
Carcinoma, Non-Small-Cell Lung pathology
Carcinoma, Squamous Cell drug therapy
Carcinoma, Squamous Cell pathology
Diarrhea chemically induced
Disease Progression
Exanthema chemically induced
Female
Gefitinib
Humans
Kaplan-Meier Estimate
Lung Neoplasms pathology
Male
Middle Aged
Neoplasm Staging
Quinazolines adverse effects
Remission Induction
Sex Factors
Treatment Outcome
Antineoplastic Agents therapeutic use
Carcinoma, Non-Small-Cell Lung drug therapy
Lung Neoplasms drug therapy
Quinazolines therapeutic use
Subjects
Details
- Language :
- Chinese
- ISSN :
- 0253-3766
- Volume :
- 29
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Zhonghua zhong liu za zhi [Chinese journal of oncology]
- Publication Type :
- Academic Journal
- Accession number :
- 17575699